The Department of Haematology is the lead centre for acute myeloid leukaemia trials in the UK.
It has a team of scientists and clinicians with an international track record centred on integrating fundamental research on haematopoietic development and leukaemia with translational and preclinical studies aimed at drug targeting of molecular abnormalities.
Research Achievements in Haematology
The main research interest of the Section is haematological oncology, which received a 5* rating in the 2001 RAE and had an outstanding 'International Profile Rating' in the 2008 assessment.
The Cardiff leukaemia research teams (CLL and AML) are internationally competitive as demonstrated by a sustained output of high quality research including papers (e.g. Blood, Journal of Clinical Oncology and Nature Genetics).
The Section itself has funding exceeding £15 million, including the CRUK/WG funded Experimental Cancer Medicine Centre (ECMC) and other charitable (Leukaemia and Lymphoma Research, Kay Kendall Leukaemia Research Fund) and industrial sources.
The national trials in AML are sponsored and lead from Cardiff and funded by CRUK, MRC, Leukaemia and Lymphoma Research Fund and other sources. This generates the largest trials in the world and has collaboration in Denmark and New Zealand and anticipates participation from France. The trial related translational programme identifies candidate agents for inclusion and supports associated biobanking and biomarker activity with in-house statistical assessment (which is part of the Experimental Cancer Medicine Centre).